Document is current
Any future updates will be listed below
-
Authors
Emma, Rosalia
Carota, Giuseppe
Partsinevelos, Konstantinos
Rust, Sonja
Sun, Ang
Giordano, Antonio
Volarevic, Vladislav
Lesmana, Ronny
Goenawan, Hanna
Barliana, Melisa Intan
Arsenijevic, Aleksandar
Kastratovic, Nikolina
Spasic, Bogdan
Giardina, Chiara
Cantali, Miriana
Pittalà, Alessandra
Saab, Miriam Wissam
Amorini, Angela Maria
Polosa, Riccardo
Caruso, Massimo
Li Volti, Giovanni
-
Funding
Funding for this research was provided by:
ECLAT Srl
- License Information
-
More Information
Article History
Received: 6 February 2025
Accepted: 10 April 2026
First Online: 22 April 2026
Declarations
:
: Not applicable.
: Not applicable.
: R.P. is full tenured professor of Internal Medicine at the University of Catania (Italy) and Medical Director of the Institute for Internal Medicine and Clinical Immunology at the same University. He has received grants from U-BIOPRED and AIR-PROM, Integral Rheumatology & Immunology Specialists Network (IRIS), Foundation for a Smoke Free World, Pfizer, GlaxoSmithKline, CV Therapeutics, NeuroSearch A/S, Sandoz, Merk Sharp & Dohme, Boehringer Ingelheim, Novartis, Arbi Group Srl., Duska Therapeutics, Forest Laboratories, Ministero dell Università e della Ricerca (MUR) Bando PNRR 3277/2021 (CUP E63C22000900006) and 341/2022 (CUP E63C22002080006), funded by NextGenerationEU of the European Union (EU), and the ministerial grant PON REACT-EU 2021 GREEN- Bando 3411/2021 by Ministero dell Università e della Ricerca (MUR) – PNRR EU Community. He is founder of the Center for Tobacco Prevention and Treatment (CPCT) at the University of Catania and of the Center of Excellence for the Acceleration of Harm Reduction (CoEHAR) at the same university. He receives consultancy fees from Pfizer, Boehringer Ingelheim, Duska Therapeutics, Forest Laboratories, CV Therapeutics, Sermo Inc., GRG Health, Clarivate Analytics, Guidepoint Expert Network, and GLG Group. He receives textbooks royalties from Elsevier. He is also involved in a patent application for ECLAT Srl. He is a pro bono scientific advisor for Lega Italiana Anti Fumo (LIAF) and the International Network of Nicotine Consumers Organizations (INNCO); and he is Chair of the European Technical Committee for Standardization on “Requirements and test methods for emissions of electronic cigarettes” (CEN/TC 437; WG4); and scientific advisor of the non-profit Foundation RIDE2Med. G.LV. is currently elected Director of the Center of Excellence for the acceleration of HArm Reduction (CoEHAR). The other authors have no relevant financial interests to disclose.
